Genincode PLC

GENinCode Plc develops and commercializes clinical genetic tests for predictive risk analysis of a patient's health based on genes. It operates in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. Its products include CARDIO inCode Score for coronary heart disease risk, LIPID inCode for familial hypercholesterolemia diagnosis and coronary risk stratification, SUDD inCode for familial heart diseases such as cardiomyopathies, channelopathies, and aortopathies related to sudden cardiac death syndrome, THROMBO inCode for hereditary thrombophilia diagnosis and thrombosis risk assessment, THROMBO inCode reproductive health for evaluating hereditary thrombophilia impact in patients with repeated miscarriages, and a risk of ovarian cancer algorithm test. The company is also involved in medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.